Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
作者： Baoan Chen , Liting Guo , Haijun Zhang , Weiwei Shao
DOI: 10.2147/DDDT.S91988
关键词:
摘要: Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal-epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by US Food Drug Administration 2011. In this review, we focus on efficacy of crizotinib compared chemotherapy advanced cancer present role personalized alternative previously treated cancer.
doaj.org参考文章(62)
Conor E. Steuer, Suresh S. Ramalingam, Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine. ,vol. 45, pp. 67- 73 ,(2015) , 10.1016/J.MAM.2015.05.004
Anish Thomas, Stephen V. Liu, Deepa S. Subramaniam, Giuseppe Giaccone, Refining the treatment of NSCLC according to histological and molecular subtypes Nature Reviews Clinical Oncology. ,vol. 12, pp. 511- 526 ,(2015) , 10.1038/NRCLINONC.2015.90
D. Kim, M. Ahn, P. Yang, X. Liu, T. De Pas, L. Crinò, S. Lanzalone, A. Polli, A. Shaw, Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) Annals of Oncology. ,vol. 23, pp. 402- 402 ,(2012) , 10.1016/S0923-7534(20)33871-0
Laird Cameron, Benjamin Solomon, New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. ,vol. 16, pp. 49- 49 ,(2015) , 10.1007/S11864-015-0367-Z
Helen Y. Zou, Luc Friboulet, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Ryohei Katayama, Dac M. Dinh, Hieu Lam, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar Patel, Divya Bezwada, Rosa L. Frias, Eugene Lifshits, Sidra Mahmood, Justin F. Gainor, Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan, Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson, Alice T. Shaw, Valeria R. Fantin, Tod Smeal, PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. ,vol. 28, pp. 70- 81 ,(2015) , 10.1016/J.CCELL.2015.05.010
Yi-Long Wu, Fei-Yu Niu, Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. OncoTargets and Therapy. ,vol. 8, pp. 999- 1007 ,(2015) , 10.2147/OTT.S64664
Mark M Awad, Alice T Shaw, ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond Clinical advances in hematology & oncology. ,vol. 12, pp. 429- 439 ,(2014)
Matthias Scheffler, Anne Schultheis, Cristina Teixido, Sebastian Michels, Daniela Morales-Espinosa, Santiago Viteri, Wolfgang Hartmann, Sabine Merkelbach-Bruse, Rieke Fischer, Hans-Ulrich Schildhaus, Jana Fassunke, Martin Sebastian, Monika Serke, Britta Kaminsky, Winfried Randerath, Ulrich Gerigk, Yon-Dschun Ko, Stefan Krüger, Roland Schnell, Achim Rothe, Cornelia Kropf-Sanchen, Lukas Heukamp, Rafael Rosell, Reinhard Büttner, Jürgen Wolf, ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability Oncotarget. ,vol. 6, pp. 10577- 10585 ,(2015) , 10.18632/ONCOTARGET.3387
Cesare Gridelli, Solange Peters, Assunta Sgambato, Francesca Casaluce, Alex A. Adjei, Fortunato Ciardiello, ALK inhibitors in the treatment of advanced NSCLC Cancer Treatment Reviews. ,vol. 40, pp. 300- 306 ,(2014) , 10.1016/J.CTRV.2013.07.002
Daniela Iacono, Rita Chiari, Giulio Metro, Chiara Bennati, Guido Bellezza, Matteo Cenci, Biagio Ricciuti, Angelo Sidoni, Sara Baglivo, Vincenzo Minotti, Lucio Crinò, Future options for ALK-positive non-small cell lung cancer Lung Cancer. ,vol. 87, pp. 211- 219 ,(2015) , 10.1016/J.LUNGCAN.2014.12.017